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Endocannabinoid (eCB) signaling has been heavily
implicated in the modulation of anxiety and depres-
sive behaviors and emotional learning. However, the
role of themost-abundant endocannabinoid 2-arach-
idonoylglycerol (2-AG) in the physiological regula-
tion of affective behaviors is not well understood.
Here, we show that genetic deletion of the 2-AG
synthetic enzyme diacylglycerol lipase a (DAGLa)
in mice reduces brain, but not circulating, 2-AG
levels. DAGLa deletion also results in anxiety-like
and sex-specific anhedonic phenotypes associated
with impaired activity-dependent eCB retrograde
signaling at amygdala glutamatergic synapses.
Importantly, acute pharmacological normalization of
2-AG levels reverses both phenotypes of DAGLa-de-
ficient mice. These data suggest 2-AG deficiency
could contribute to the pathogenesis of affective
disorders and that pharmacological normalization of
2-AG signaling could represent an approach for the
treatment of mood and anxiety disorders.
INTRODUCTION
Endogenous cannabinoid (eCB) signaling is mediated by canna-
binoid receptors (type 1: CB1 and type 2: CB2), which are acti-
vated by several endogenous ligands including anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) (Kano et al., 2009; Pio-
melli, 2003). Over the past decade, eCB signaling has been impli-
cated in the regulation of multiple physiological functions in the
nervous system and periphery, including a primary role in the
modulation of anxiety and depressive behaviors (Hill and Patel,
2013; Kathuria et al., 2003; Lutz, 2009; Ruehle et al., 2012). Spe-
cifically, pharmacological blockade or genetic deletion of CB11644 Cell Reports 9, 1644–1653, December 11, 2014 ª2014 The Autreceptors increases anxiety in multiple animal models and in hu-
mans under some conditions (Christensen et al., 2007; Gamble-
George et al., 2013; Hill and Gorzalka, 2004; Moreira et al., 2009;
Patel and Hillard, 2006). Consistent with these data, anxiety in
various animal models is decreased by low doses of exogenous
cannabinoids (Patel and Hillard, 2006; Rey et al., 2012) and by
pharmacological or genetic augmentation of eCB levels (Her-
manson et al., 2013; Kathuria et al., 2003; Moreira et al., 2008;
Patel and Hillard, 2006; Rossi et al., 2010; Sciolino et al., 2011;
Sumislawski et al., 2011). These data strongly suggest a key
role for eCB signaling in the physiological regulation of anxiety
and depressive behaviors.
2-AG is the most abundant eCB ligand in the brain and is the
primary mediator of phasic eCB-mediated retrograde suppres-
sion of neurotransmitter release in the nervous system (Gao
et al., 2010; Ohno-Shosaku et al., 2012; Tanimura et al., 2010).
The synaptic signaling pools of 2-AG are synthesized and
degraded primarily by the postsynaptic diacylglycerol lipase a
(DAGLa) and presynaptic monoacylglycerol lipase (MAGL),
respectively, in the adult brain (Dinh et al., 2002). Several recent
studies have demonstrated that pharmacological elevation of 2-
AG signaling can reduce anxiety-like behaviors in animal models
(Busquets-Garcia et al., 2011; Sciolino et al., 2011; Sumislawski
et al., 2011; Zhong et al., 2014), whereas some clinical studies
have demonstrated reduced peripheral 2-AG levels in patients
with posttraumatic stress disorder and women with major
depression compared to control subjects (Hill et al., 2008,
2013). Although these data suggest a close association between
2-AG signaling and affective pathology, a causal relationship
between endogenous 2-AG signaling and the physiological
expression of anxiety and depressive behaviors has not been
demonstrated. Here, we show Dagla knockout mice exhibit re-
ductions in limbic 2-AG levels associated with anxiety-like be-
haviors and anhedonia, both of which are reversed by acute
pharmacological normalization of 2-AG deficiency. These data
provide causal evidence supporting 2-AG signaling deficiency
as a key mechanism subserving development of affectivehors
pathology and support pharmacological 2-AG augmentation as
a viable treatment approach for mood and anxiety disorders.
RESULTS
Biochemical Validation of DAGLa/ Mice
HomozygousDagla knockoutmice (DAGLa/)miceweregener-
ated as described in Experimental Procedures and identified by
standard PCR approaches, exhibiting the expected shift in size
of amplification product associatedwith targeting cassette inser-
tion upstream of exon 8 of theDagla gene (Figure 1A). Adult male
and female DAGLa/ mice showed a complete lack of brain
DAGLa protein expression (p < 0.0001 for both sexes) as as-
sessed by western blot analysis and reductions in enzymatic ac-
tivity (p < 0.05 for both sexes), confirming effectiveness of the
gene-disruption strategy (Figures 1B–1D). Mass spectrometry
analysis revealed a significant reduction of forebrain 2-AG levels
(male p < 0.05; female p < 0.0001; Figure 1E). To provide insight
into the specific diacylglycerol (DAG) species thatmay beDAGLa
substrates in vivo,we analyzed levels of arachidonate-containing
DAGs. The most abundant arachidonic acid (AA)-containing
DAG detected, 1-stearoyl-2-arachidonoylglycerol (SAG), was
increased in both male (p < 0.0001) and female (p < 0.001)
DAGLa/ forebrains (Figure 1F), indicating its importance as a
physiological substrate for DAGLa in the brain and confirming
previous work in cultured neuroblastoma cells (Jung et al.,
2007). Several less-abundant AA-containing DAG species were
also detected, some of which also displayed sex-specific
changes in DAGLa/ mice (Figures S1A–S1J). In contrast,
none of the non-AA-containing DAGs measured were different
between genotypes of either sex (data not shown). Consistent
with reductions in 2-AG levels, the primary hydrolytic metabolite
of 2-AG,AA,wasalso reduced inDAGLa/mice (male p<0.001;
femalep<0.01; Figure 1G). Therewerenochanges in levels of the
othermajor eCB, anandamide (Figure 1H). Brain regional analysis
revealed reductions in 2-AGandAA in theprefrontal cortex (PFC),
amygdala, and striatum of bothmale and female DAGLa/mice
(Figures 1I and 1J). Levels of the non-eCB monoacylglycerol, 2-
oleoylglycerol (2-OG), were also significantly reduced in the
PFC, amygdala, and striatum of male and female DAGLa/
mice (Figure S1K). These data indicate DAGLa/ mice have
the expected alterations in DAGLa protein, enzymatic activity,
and 2-AG metabolism with reduced 2-AG levels, increased
2-AG precursor levels, and reduced levels of the 2-AG degrada-
tion product AA. Lastly, given the increasing interest in using pe-
ripheral eCB levels as biomarkers for neuropsychiatric diseases,
we measured plasma 2-AG, AEA, and AA concentrations and
found no changes in DAGLa/mice relative towild-type (WT) lit-
termates (Figures 1K–1M). Thus, plasma 2-AG levels are not
dependent on DAGLa under basal conditions.
DAGLa Deletion Increases Anxiety-like Behaviors
Having established that DAGLa deletion results in reduced cen-
tral 2-AG levels, we next evaluated the effects of this 2-AG defi-
ciency on anxiety- and depressive-like behaviors. Separate
cohorts of male and female DAGLa/ mice and WT littermates
were sequentially tested for a series of anxiety- and depressive-
like behaviors (Figure 2). In the open-field assay, male (p < 0.01)Cell Reand female (p < 0.05) DAGLa/ mice showed reduced vertical
exploration without changes in total distance traveled, indicating
decreased exploratory drive without gross motor abnormality
(Figures 2A and 2B). Only female mice showed a reduction in
percent center distance traveled (p < 0.05) suggestive of
enhanced anxiety-like behavior (Figures 2A and 2B). In the
light-dark box (L-D box) test, both male (p < 0.01) and female
(p < 0.01) DAGLa/mice showed reduced exploratory distance
traveled, reduced percent light-zone ambulation (males p <
0.001 and female p < 0.01), and reduced time spent in the light
compartment (males p < 0.05 and females p < 0.01; Figures
2C and 2D). We next testedmice using a more ethologically rele-
vant behavioral assay, the novelty-induced hypophagia (NIH)
test, which is highly sensitive to eCB modulation (Gamble-
George et al., 2013). In this test, bothmale and female DAGLa/
mice showed an increase in feeding latency as demonstrated by
a difference in the cumulative feeding latency distribution (males
p < 0.0001 and females p < 0.0001 by Kolmogorov-Smirnov
[K-S] test), increased mean feeding latency (females p <
0.001), and reduced consumption (males p < 0.05 and females
p < 0.05; Figures 2E and 2F). To exclude the possibility that
impaired motor coordination contributes to the observed behav-
ioral effects, we tested DAGLa/ mice on the accelerating
rotarod but did not find any differences in motor performance
between genotypes (Figures S2A and S2B).
DAGLa Deletion Results in Sex-Specific Depressive-like
Behavior
We next examined more-traditional depressive-like behaviors
using the sucrose preference test (SPT) and the tail suspension
test (TST). No differences in sucrose preference, sucrose
consumption, or water consumption (not shown) were observed
in male DAGLa/ mice relative to WT littermates (Figure 2G).
In contrast, female DAGLa/ mice showed reduced sucrose
preference (p < 0.001), reduced sucrose consumption
(p < 0.01), and increased water consumption (p < 0.001; not
shown) over the course of the experiment after normalization
to body weight (Figure 2H and see Figures S2C and S2D for
body weight data). Neither male nor female DAGLa/ mice
showed differences in immobility time during the tail suspension
test relative to WT littermates (Figures 2I and 2J).
DAGLa Deletion Impairs Amygdala eCB Retrograde
Synaptic Signaling
eCB signaling, and specifically 2-AG signaling, is known to inhibit
excitatory glutamatergic transmission in the amygdala (Azad
et al., 2003; Domenici et al., 2006; Yoshida et al., 2011), and
eCB-mediated reductions in anxiety likely require CB1-mediated
inhibition of glutamate, but notGABA, release (Ha¨ring et al., 2012;
Rey et al., 2012; Ruehle et al., 2013). Therefore, we hypothesized
that DAGLa/ mice would have impaired eCB-mediated
suppression of basolateral amygdala (BLA) glutamatergic trans-
mission, which could contribute to the observed anxiety-like
behavioral phenotype. To test this hypothesis, we used the
most well-established form of 2-AG-mediated retrograde endo-
cannabinoid signaling expressed widely throughout the CNS,
depolarization-induced suppression of excitation (DSE) (Alger,
2002; Tanimura et al., 2010). Whole-cell patch-clamp recordingsports 9, 1644–1653, December 11, 2014 ª2014 The Authors 1645
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fromBLApyramidal neurons revealed that postsynaptic depolar-
ization caused a transient suppression of excitatory postsynaptic
current (EPSC) amplitude (Yoshida et al., 2011; Figure 3A), which
was blocked by preincubation with the CB1 receptor antagonist
rimonabant (p < 0.0001). BLADSEwas attenuated by pharmaco-
logical inhibition of DAGL with tetrahydrolipstatin (THL) (p < 0.01;
Figure 3B) and by postsynaptic calcium chelation with 40 mM
1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-tetra-acetic acid
(BAPTA) (p < 0.01; Figure 3C). Importantly, DSE was essentially
absent in DAGLa/mice relative to wild-type littermate controls
(p < 0.0001; Figure 3D). Because 2-AG levels were decreased in
the striatum as well, we also confirmed that DSE was absent in
this brain region of DAGLa/mice (Figure S3). These data sup-
port 2-AGas akeymediator of retrograde 2-AGsignaling at excit-
atory synapses (Gao et al., 2010; Tanimura et al., 2010).
Lastly, we evaluated potential compensatory consequences
of the prolonged impairment of eCB-mediated inhibition of gluta-
matergic signaling on measures of excitatory synaptic transmis-
sion,membrane properties, and excitability of BLA principle neu-
rons of male and female DAGLa/ mice. Neither male nor
female DAGLa/mice exhibited changes in membrane proper-
ties or cellular excitability (Figures 3E and 3G). However, there
was a slight reduction of spontaneous EPSC (sEPSC) amplitude
specifically in females, whereas neither sex exhibited significant
changes in sEPSC interevent interval (IEI) (Figures 4F and 4H).
Overall, these measures indicate no major compensatory
changes in basal glutamatergic transmission or cell excitability
as a result of long-term DAGLa deletion.
2-AG Restoration Normalizes the Behavioral Phenotype
of DAGLa/ Mice
Thus far, our data clearly support necessity for 2-AG signaling in
the physiological regulation of anxiety and depressive behaviors.
However, establishing a causal link between 2-AG signaling defi-
ciency and the behavioral phenotypes observed in DAGLa/
mice also requires experimental support for sufficiency of 2-
AG signaling in the regulation of physiological anxiety and
depressive behaviors. Therefore, we utilized a pharmacological
approach to restore 2-AG levels in DAGLa/ mice and deter-
mined the impact on the behavioral phenotype of DAGLa/
mice. Administration of the MAGL inhibitor JZL-184 (20 mg/kg)
robustly increases brain 2-AG levels in WT mice (Long et al.,
2009; Figure S4), suggesting this approach could also be useful
for restoring deficient 2-AG levels in DAGLa/ mice.
In the L-D box, vehicle-treated DAGLa/ mice again ex-
hibited anxiety-like behavior relative to WT vehicle-treated
mice (p < 0.05 for both measures; Figures 4A and 4B), whereasFigure 1. Characterization and Validation of DAGLa/ Mice
(A) Conventional PCR gel showing the amplified products from primers that annea
upstream of exons 8. The resulting product in DAGLa/ mice demonstrates the
cassette.
(B and C) Representative western blot gel from male ‘‘M’’ and female ‘‘F’’ (B) and
(D) DAGL activity in forebrain extracts from male and female DAGLa/ mice.
(E–H) Forebrain levels of 2-AG, 1-steroyl-2-arachidonoyl glycerol (SAG), arachid
(I and J) 2-AG and AA levels in the prefrontal cortex (PFC), amygdala, and striatu
(K–M) Plasma levels of 2-AG, AA, and AEA in DAGLa/ mice.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by Sidak’s post hoc test. Error
Cell Reboth percent light distance and light time were significantly
higher in JZL-184-treated DAGLa/ mice relative to vehicle-
treated DAGLa/ mice (p < 0.05 and p < 0.01, respectively).
Ambulatory distance was not affected by any treatment (Fig-
ure 4C). In the SPT, baseline sucrose preference was again
significantly lower in female DAGLa/ mice relative to WT
mice, confirming our previous data (p < 0.001; Figure 4D). After
establishment of a baseline preference, JZL-184 was adminis-
tered to DAGLa/ mice whereas WT mice received vehicle
injections. After 1 day of JZL-184 treatment, the sucrose prefer-
ence of DAGLa/mice remained significantly lower than that of
vehicle-treated WT mice, but on the second day of drug treat-
ment, sucrose preference was not significantly different between
vehicle-treated WT mice and DAGLa/ mice treated with
JZL-184 (p > 0.05; Figure 4D). Importantly, sucrose preference
deficits in DAGLa/ mice relative to WT re-emerged after a
24 hr drug washout period (p < 0.05; Figure 4D, recovery). Inter-
estingly, although we replicated the robust anxiety-like effect in
DAGLa/ mice in the NIH assay, JZL-184 did not reverse the
increased feeding latency exhibited by DAGLa/ mice (Fig-
ure 4E). To confirm this dose of JZL-184 increased 2-AG levels
in DAGLa/ mice, we measured 2-AG 2 hr after 20 mg/kg
JZL-184 treatment. Vehicle-treated DAGLa/mice showed sig-
nificant reductions in 2-AG levels in the PFC (p < 0.01), amygdala
(p < 0.0001), and striatum (p < 0.0001; Figures 4F–4H). Impor-
tantly, treatment with 20 mg/kg JZL-184 significantly increased
2-AG levels in the PFC (p < 0.01), amygdala (p < 0.05), and stria-
tum (p < 0.05) relative to vehicle-treated DAGLa/ mice, indi-
cating this dose was sufficient to at least partially restore 2-AG
levels in DAGLa/ mice. These data support sufficiency of
2-AG signaling in regulating anxiety and depressive behaviors.
DISCUSSION
To investigate the physiological role of endogenous 2-AG
signaling in the regulation of anxiety and depressive behaviors,
we utilized a genetic approach to delete a primary 2-AG
synthetic enzyme, DAGLa. We find that DAGLa/ mice have
the expected decreases in 2-AG tissue levels and decreases
in AA consistent with other DAGLa/ mouse lines (Gao et al.,
2010; Tanimura et al., 2010; Yoshino et al., 2011). Comparison
to previous studies revealed some key differences between
our findings and published results. For example, Gao et al.
reported 75% reduction in whole-brain 2-AG and AA in
DAGLa/ mice, whereas our bulk 2-AG reductions appeared
much less dramatic. Reasons for this discrepancy are unclear
but could be related to the fact we specifically analyzedl to endogenous DNA sites that flank the targeting cassette, which was inserted
expected 250 bp shift as a result of the successful insertion of the targeting
DAGLa/ forebrain, which is summarized in bar graph (C). KO, knockout.
onic acid (AA), and AEA in male and female DAGLa/ and WT mice.
m of male and female DAGLa/ mice.
bars indicate SEM. See also Figure S1.
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forebrain rather than whole brain. In addition, Gao et al. showed
an 50% reduction in 2-AG levels in DAGLb/mice (Gao et al.,
2010), suggesting this enzyme also contributes to bulk brain 2-
AG measurements and that the residual forebrain 2-AG levels
observed in our DAGLa/mice may be synthesized by DAGLb.
There may also be significant regional heterogeneity in the ef-
fects of DAGLa deletion on 2-AG levels such that forebrain ana-
lyses may underestimate highly localized decreases observed in
the subregional analysis. This suggestion is supported by the
dramatic region-specific reductions in 2-AG levels observed in
DAGLa/ mice, which confirms robust 2-AG deficiency in key
limbic brain regions regulating anxiety and depressive behaviors
including the PFC and amygdala. We also show that the levels of
SAG and several other AA-containing DAGs are elevated in the
forebrain of DAGLa/mice, consistent with previous findings in
cultured cells (Jung et al., 2007), revealing these lipids are the
precursors of 2-AG formation in vivo. Lastly, reductions in brain
AEA have also been reported in DAGLa/ mice (Gao et al.,
2010; Tanimura et al., 2010). Whereas we did not observe reduc-
tions in forebrain AEA levels in our mice, future studies will be
aimed at enhancing detection and quantification of brain
regional AEA differences to clarify this discrepancy.
Upon confirmation that DAGLa/ mice represented a vali-
dated limbic 2-AG deficiency model, we undertook a compre-
hensive behavioral analysis of DAGLa/ mice to test the
hypothesis that endogenous 2-AG signaling is a critical regulator
of affective behavior. Our data revealed anxiety-like behaviors
in both male and female DAGLa/ mice, whereas only female
mice exhibit anhedonia as demonstrated by a reduction in su-
crose preference. Overall ambulation in the open field and motor
coordination on the accelerating rotarod were unaffected by
DAGLa deletion, indicating that the observed differences in anx-
iety-like and depressive behaviors were not likely confounded
by motor deficits per se. With regard to measures of anxiety,
DAGLa/ mice showed increased anxiety-like behavior in the
open-field, L-D-box, and NIH assay, thus supporting a primary
role for 2-AG signaling in the regulation of anxiety-like behavior
(Patel and Hillard, 2008). In contrast, only female DAGLa/
mice exhibited anhedonia, whereas neither male nor female
DAGLa/ mice exhibited despair-like behavior in the TST. The
data herein suggest that 2-AG signaling is selectively involved
in the regulation of a discrete behavioral dimension of depres-
sion, namely anhedonia, whereas it has broader multidimen-
sional effects on anxiety-related behavior.
Importantly, we also found that pharmacological elevation of
2-AG levels in DAGLa/ mice reversed anxiety behavior in the
L-D box and anhedonia in the SPT, but it was unable to reverse
anxiety in the NIH assay. Because the NIH assay is extremely
sensitive to CB1 signaling deficiency (Gamble-George et al.,
2013), it is possible that more-complete 2-AG restoration orFigure 2. DAGLa Deletion Increases Anxiety-like and Depressive Beha
(A and B) Behavioral analysis of male (A) and female (B) DAGLa/ mice in the o
(C and D) Behavioral analysis of male (C) and female (D) DAGLa/ mice in the li
(E and F) Behavioral analysis of male (E) and female (F) DAGLa/ mice in the N
(G and H) Behavioral analysis of male (G) and female (H) DAGLa/ mice in the s
(I and J) Behavioral analysis of male (I) and female (J) DAGLa/ mice in the tail
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by ANOVA, t test, or K-S test a
Cell Relonger duration of restoration would be required to see reversal
in this test. In support of this, 2 days of JZL-184 treatment was
required to produce a reversal of the anhedonic phenotype of
DAGLa/ mice. These data are consistent with recent findings
demonstrating that pharmacological elevation of 2-AG reduces
stress-induced anxiety (Sciolino et al., 2011; Sumislawski
et al., 2011; Zhong et al., 2014). Taken together, our data
showing that the increase in anxiety and depressive behavior
in DAGLa/ mice is reversed by normalization of deficient
2-AG levels provide causal evidence to support 2-AG signaling
deficiency as the mechanism subserving the behavioral pheno-
type of DAGLa/mice. However, some caveats to this interpre-
tation remain. For example, in addition to 2-AG reductions, we
detected profound loss of arachidonic acid throughout the brain,
potentially confounding our interpretation of the causal role for
2-AG deficiency in our observed phenotypes. However, inhibi-
tion of 2-AG degradation also produces dramatic reductions in
AA (Long et al., 2009) but reduces anxiety-like and depressive
behaviors (Busquets-Garcia et al., 2011; Sciolino et al., 2011;
Sumislawski et al., 2011; Zhong et al., 2014); thus, reductions
in AA levels cannot explain the anxiety-like behavior observed
in DAGLa/ mice. It is also possible that reductions in levels
of other monoacylglycerols such as 2-OG could contribute to
the observed phenotype of DAGLa/ mice: a hypothesis that
will require further testing.
Increased anxiety and depressive behaviors in humans and
laboratory animals is highly associated with increased activity
in the amygdala (Etkin andWager, 2007; Levine et al., 2001; Roo-
zendaal et al., 2009). Given that one key physiological function of
2-AG signaling is retrograde synaptic suppression, we evaluated
the effects of DAGLa deletion on eCB-mediated short-term
synaptic suppression at amygdala glutamatergic synapses.
BLA DSEwas absent in DAGLa/mice, suggesting an impaired
activity-dependent feedback inhibition of BLA glutamatergic
transmission in DAGLa/ mice. These data are consistent
with previous studies showing impaired DSE and depolariza-
tion-induced suppression of inhibition in hippocampus and
cerebellum of DAGLa/ mice (Gao et al., 2010; Tanimura
et al., 2010). Although the behavioral phenotype of DAGLa/
mice is likely a consequence of perturbed limbic circuit interac-
tions, rather than a consequence of impaired DSE at a single
synapse, these data confirm that 2-AG signaling is impaired at
one key synapse heavily implicated in the regulation of affective
behavior and emotional learning.
These data could also have implications for cannabis-use dis-
orders, which are expected to rise given recent shifts in the pro-
hibition against cannabis use. Specifically, the most common
reason cited for continued cannabis use in chronic users is
reduction in tension and anxiety (Hyman and Sinha, 2009; Reilly
et al., 1998), and stress ‘‘coping’’ motives are heavily reportedvior
pen-field assay. df, degrees of freedom.
ght-dark box test (L/D box).
IH assay.
ucrose preference test (SPT).
suspension test (TST).
s indicated in the panel. Error bars indicate SEM. See also Figure S2.
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Figure 3. DAGLa Deletion Impairs eCB Modulation of Amygdala Glutamatergic Transmission
(A) Representative example of DSE in the BLA with arrows indicating time of 10 s depolarization from 70 mV to +30 mV.
(B) Effects of the CB1 receptor antagonist rimonabant and DAGL inhibitor THL on BLA DSE. AUC, area under the curve.
(C) Effects of postsynaptic calcium chelation with BAPTA on BLA DSE.
(D) Effects of DAGLa deletion on BLA DSE.
(E and F) Analysis of BLA neuron (E) membrane properties and excitability and (F) sEPSC amplitude and interevent interval (IEI) in male DAGLa/ mice. AHP,
afterhyperpolarization; AP, action potential.
(G and H) Analysis of BLA neuron (G) membrane properties and excitability and (H) sEPSC amplitude and IEI in female DAGLa/ mice.
**p < 0.01; ****p < 0.0001 by ANOVA, Sidak’s post hoc analysis, or t test as indicated in the panel. Error bars indicate SEM. See also Figure S3.by cannabis users (Bujarski et al., 2012; Chabrol et al., 2005;
Fox et al., 2011; Hyman and Sinha, 2009). These data
are consistent with the ‘‘tension-reduction hypothesis’’ of sub-1650 Cell Reports 9, 1644–1653, December 11, 2014 ª2014 The Autstance use, which posits that negative reinforcement is a
primary driver of continued substance use and that inherent
negative affect associated with anxiety could drive cannabishors
Figure 4. JZL-184 Reverses Anxiety and
Depressive Behaviors in DAGLa/ Mice
(A–C) Effects of DAGLa deletion and JZL-184
treatment on percent light distance traveled, light
time, and total ambulatory distance in the L-D box.
(D) Effects of DAGLa deletion and JZL-184 treat-
ment on sucrose preference in female mice. Note
JZL-184 was administered on 2 consecutive days
2 hr prior to testing, whereas recovery represents
testing under vehicle-treatment conditions 24 hr
after the last drug treatment.
(E) Effects of DAGLa deletion and JZL-184 treat-
ment on latency to feed in the NIH assay.
(F–H) Effects of DAGLa deletion and JZL-184
treatment on 2-AG levels in the PFC (F), amygdala
(G), and striatum (H).
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by
ANOVA followed by Sidak’s post hoc analysis or
K-S test as indicated in the panel. Error bars
indicate SEM. See also Figure S4.use in an attempt to reduce symptom severity (see Buckner
et al., 2007). Our data provide compelling support for an ‘‘endo-
cannabinoid deficiency’’ state causing anxiety and depressive
effects (Russo, 2008), which could drive cannabis use in an
attempt to relieve these symptoms. That restoration of 2-AG
signaling reverses anxiety and depressive behaviors induced
by eCB deficiency supports therapeutic approaches aimed at
normalizing endocannabinoid deficiency to treat cannabis-use
disorders and facilitate abstinence in some individuals (Clapper
et al., 2009).Cell Reports 9, 1644–1653, DeCB1 receptor activity and AEA
signaling have been heavily implicated
in the regulation of anxiety- and depres-
sive-like behaviors (Bambico et al.,
2010; Gobbi et al., 2005; Hill and Patel,
2013; Hill et al., 2010; Kathuria et al.,
2003; Lutz, 2009; Moreira et al., 2008;
Viveros et al., 2005). However, the physi-
ological function of the most-abundant
eCB ligand in the CNS, 2-AG, has re-
mained relatively elusive. Our data pro-
vide causal evidence for 2-AG signaling
in the physiological regulation of anxiety-
and depressive-like behaviors and sug-
gest the hypothesis that 2-AG deficiency
could contribute to the pathogenesis of
somemood and anxiety disorders. These
data also suggest pharmacological ap-
proaches aimed at normalizing 2-AG
deficiency could represent a viable eCB-
based therapeutic strategy for the treat-
ment of mood and anxiety disorders.
EXPERIMENTAL PROCEDURES
Generation of DAGLa/ Mice
All studies were carried out in accordance with the
NIH Guide for the Care and Use of Laboratory An-imals and approved by the Vanderbilt University Institutional Animal Care and
Use Committee. DAGLa/ mice were generated by disruption of exon 8 and
were maintained on a C57Bl6/N background by interbreeding DAGLa+/mice.
Further details are described in the Supplemental Experimental Procedures.
Mass Spectrometry
Lipids from whole brain and brain regions were extracted in acetonitrile
andmethanol, respectively,containingtheappropriatedeuteratedstandardsand
analyzed by liquid chromatography-tandemmass spectrometry (LC-MS/MS) in
selective reaction-monitoring mode as described previously (Hermanson et al.,
2013) and in detail in the Supplemental Experimental Procedures.cember 11, 2014 ª2014 The Authors 1651
Electrophysiology
Electrophysiological recordings and DSE experiments were conducted from
BLA principle cells in the presence of 50 mM picrotoxin to block fast
GABAergic transmission as previously described (Ramikie et al., 2014) and
detailed in the Supplemental Experimental Procedures. Membrane properties
of BLA neurons were analyzed as previously described (Sumislawski et al.,
2011).
Behavioral Analysis
Adult mice (9–16 weeks) were housed on a 12:12 light-dark cycle with lights
on at 06:00. All experiments were conducted during the light phase. Food
and water were available ad libitum. DAGLa/ mice were sequentially tested
in the open-field test, light-dark box, novelty-induced hypophagia assay,
sucrose preference test, tail suspension test, and accelerating rotarod
as described in the Supplemental Experimental Procedures. Tests were
conducted at least 48 hr apart. Not all mice were evaluated in every test,
and male and female cohorts were tested and analyzed separately.
Statistical Analysis
All data were analyzed using GraphPad Prism version 6. Data that included
more than two groups or two factors were analyzed by one-way or two-way
ANOVA, respectively, as indicated in the figures, with post hoc Sidak’smultiple
comparisons test. Multiplicity corrected p values are noted in figures. For
analysis of two groups, an unpaired two-tailed t test was used. For analysis
of cumulative feeding latencies, K-S test was used. p < 0.05 was considered
significant throughout. Data are presented as mean ± SEM throughout.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.11.001.
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